Ibrutinib-MPEA |
Katalog-Nr.GC38106 |
Ibrutinib-MPEA (Verbindung 20) ist ein Ibrutinib-Derivat. Ibrutinib ist ein kovalenter und irreversibler Inhibitor der Bruton-Tyrosinkinase (BTK), der zur Behandlung hÄmatologischer Malignome eingesetzt wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1710768-30-1
Sample solution is provided at 25 µL, 10mM.
Ibrutinib-MPEA (Compound 20) is ibrutinib derivative. Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK) that has been used to treat haematological malignancies[1].
[1]. Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Org Biomol Chem. 2015 May 14;13(18):5147-57.
Average Rating: 5
(Based on Reviews and 34 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *